Latest Conference Coverage
Use of these agents is associated with a much lower incidence of hypercalcemia compared with the use of calcium carbonate or calcium acetate.
Meta-analysis reveals a significantly increased risk of kidney stones only in male patients with kidney cancer.
Calciphylaxis was 75% less likely to develop in patients who received the drug rather than placebo.
Over 52 weeks, the drug maintained hemoglobin levels while decreasing IV iron use in dialysis patients with anemia.
Researchers in the Netherlands report results from an autopsy study of diabetic nephropathy patients.
In adjusted analyses, serum phosphorus levels independently predicted glucose disposal rate.
Benefit seen among anemia and hemodialysis patients with hemoglobin levels below 10 g/dL.
Each 0.5 mg/dL increment in serum phosphorus associated with 58% increased odds of coronary heart failure (CHF).
Aspirin and clonidine increased the risk of major bleeding and clinically important hypotension in acute kidney injury (AKI).
Renal events are significantly less likely if erythropoiesis-stimulating agents are started at hemoglobin levels below 11 g/dL.
Tight blood pressure control slows the rate of increase in total kidney volume and reduces left ventricular index.
Periodontal disease is associated with a significant 4.2-fold greater incidence of chronic kidney disease (CKD).
Rates for infection-, gastrointestinal-, and cardiac-related adverse events are lower than with sevelamer carbonate or calcium acetate.
New finding on vitamin B6 is the opposite of what investigators hypothesized on patients with anemia.
Plant-based diet had the lowest urinary phosphorus excretion, whereas an inorganic-based diet had the highest.
Adjuvant chemotherapy is associated with better survival among patients with advanced nonmetastatic bladder cancer.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival in intermediate-risk prostate cancer.
Adding bicalutamide improves overall survival among patients with advanced nonmetastatic hormone-naïve prostate cancer.
Cancer-specific and overall survival is decreased in men with intermediate-risk versus low-risk tumors.
Overweight or obese patients treated with targeted therapy for metastatic clear-cell renal cell carcinoma found to live longer.
In a study of 4,736 patients with metastatic renal cell carcinoma, use of the drugs was associated with a nearly 22% decreased risk of death.
Sorafenib or sunitinib given after surgery for advanced renal cell carcinoma does not improve progression-free survival, study shows.
Researchers observed a significant 36% decreased overall and prostate cancer-specific mortality.
It has implications for treatment decisions and prognosis.
In a phase 2 trial, 72% of patients with high-grade clinical nonmuscle-invasive bladder cancer had a complete response at 3 months.
The 4Kscore enables better identification of men who harbor high-grade prostate cancer.
The 5-year risk of overall mortality is decreased by 50% compared with androgen deprivation therapy alone.
This medication sequence was associated with longer progression-free and overall survival compared with the reverse.
Researchers found elevated familial risks for testicular, prostate, bladder, and kidney cancers.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)